Combating Drug-Resistant Infections Globally. Company Presentation
|
|
- Leona Murphy
- 5 years ago
- Views:
Transcription
1 Combating Drug-Resistant Infections Globally Company Presentation
2 Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of Actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors, including: whether XERAVA TM (eravacycline) will be successfully distributed and marketed; whether our cash resources will be sufficient to fund our continuing operations for the period we anticipate; whether clinical trials for our product candidates will be successful; whether the results from such clinical trials or studies will be sufficient to warrant regulatory approval; whether approvals will be received for our clinical candidates from the United States Food and Drug Administration or equivalent foreign regulatory agencies on a timely basis or at all; and other factors discussed in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect Tetraphase s current views with respect to future events, and Tetraphase assumes no obligation to update any forward-looking statements except as required by applicable law. 2
3 Multidrug-Resistance (MDR) is a Growing Crisis Superbug From India Spread Far and Fast, Study Finds By Brianna Abbott January 27, 2019 November 6, 2018 How antibiotic resistance can take us back to the dark ages Drug resistant superbugs are killing 33,000 in Europe each year By Kate Kelland November 5, 2018 April 3, 2018 Nightmare bacteria, resistant to almost every drug, stalk U.S. hospitals By Liz Szabo Number of new antibiotics has fallen sharply since 2000 By Julie Kollewe January 23, 2018 April 3, 2018 CDC: Drug-resistant 'nightmare bacteria' pose growing threat By Marilyn Marchione 3
4 Tetraphase Pharmaceuticals: Corporate Highlights Novel Antibiotics for Serious and Life-Threatening MDR Infections Launched in the U.S. Significant Market Opportunity Novel Pipeline Strong Balance Sheet Strong Leadership XERAVA TM (eravacycline) Broad Label in ciai Differentiated Antibiotics Cash runway into Q Experienced management team FDA and EMA approved for treatment of complicated intraabdominal infections (ciai) Product opportunity of up to 2 million patient days of therapy Proprietary platform enables creation of novel tetracycline compounds $108 million in cash and cash equivalents as of Dec. 31, 2018 Track record of success in anti-infective development, regulatory approval and commercialization 4
5 A Strong Pipeline Led by XERAVA Product/Candidate Route of Administration Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved XERAVA Complicated IAI IV TP-271 Respiratory Infections, CABP IV Oral TP-6076 MDR Infections IV TP-2846 Acute Myeloid Leukemia IV 5
6 XERAVA: Novel Antibiotic Approved to Treat Serious Infections Novel, fully-synthetic fluorocycline FDA and EMA approved for complicated intra-abdominal infections Potent activity against broad spectrum of bacteria Gram-negative and Gram-positive Anaerobic and atypical Multidrug-resistant: ESBLs, AmpC, VRE, MRSA ESBL: extended-spectrum beta-lactamase; VRE: vancomycin-resistant enterococci; MRSA: methicillin resistant Staphylococcus aureus; AmpC: AmpC beta-lactamases 6
7 *MIC 90 (ug/ml) XERAVA: Demonstrates Potent In Vitro Coverage XERAVA Tigecycline Ceftazidime Pip/Tazo Meropenem E. coli MDR (n=1388) E. coli, ESBL (n=195) E. coli, CRE (n=277) K. pneumonia MDR (n=956) K. pneumonia, ESBL (n=230) K. pneumonia, CRE (n=1024) A. baumannii MDR (n=1735) A. baumannii, CRAB (n=1792) Multidrug-Resistant Pathogens *MIC 90 : Minimum Inhibitory Concentration: Lowest concentration of the antibiotic at which 90% of the isolates were inhibited Sources: CANWARD 2014, IHMA , IHMA 2015 and IHMA
8 Two Successful Phase 3 Clinical Trials Showing High Clinical Cure Rates Against Resistant Pathogens Baseline Pathogen (No./Total no.) XERAVA % Enterobacteriaceae (277/314) 88.2 CEPH-R (38/42) 90.5 ESBL confirmed (32/36) 88.9 CRE confirmed (1/1) 100 MDR (35/39) 89.7 Acinetobacter species (13/13) 100 CEPH-R (13/13) 100 ESBL confirmed (5/5) 100 CRAB confirmed (3/3) 100 MDR (12/12) 100 Sources: Solomkin J. et al. JAMA Surgery 2017; 152(3): Ditch, et al. Poster 629. Presented at ASM Microbe 2018, Atlanta, GA 8
9 Complicated Intra-Abdominal Infections (ciai) Infection proceeding beyond the source organ into the peritoneal space Sites of Infection (%) in the ICU 3 IAI represents 1 of 5 ICU infections Second most prevalent site of infection in the ICU Respiratory tract Second leading cause of infectious mortality in the ICU Abdominal Bloodstream Renal/urinary tract Second most commonly identified cause of severe sepsis in the ICU Skin Catheter related CNS Others 2.9 Sources: 1. Solomkin JS, et al. Clin Infect Dis. 2010;50: ; 2. Lopez et al. World Journal of Emergency Surgery 2011, 6:7 ; 3. Vincent JL et al. JAMA. 2009;302(21):
10 ESBL Rates Among Enterobacteriaceae Isolates Across U.S. Pacific (9.1%) E. coli 11.2% K. pneumoniae 8.3% K. oxytoca 6.5% P. mirabilis 2.7% USA National (12.2%) E. coli 11.9% K. pneumoniae 16.0% K. oxytoca 10.0% P. mirabilis 4.8% Mountain (12.8%) E. coli 13.2% K. pneumoniae 11.9% K. oxytoca 12.1% P. mirabilis 13.4% WestNorth Central (4.4%) E. coli 5.2% K. pneumoniae 3.2% K. oxytoca 6.5% P. mirabilis 1.7% EastNorth Central (8.8%) E. coli 10.1% K. pneumoniae 8.7% K. oxytoca 9.4% P. mirabilis 3.9% New England (9.7%) E. coli 10.0% K. pneumoniae 11.2% K. oxytoca 13.0% P. mirabilis 1.9% Mid-Atlantic (23.2%) E. coli 20.1% K. pneumoniae 34.7% K. oxytoca 8.6% P. mirabilis 7.2% South Atlantic (19.9%) E. coli 17.6% K. pneumoniae 25.9% K. oxytoca 20.0% P. mirabilis 5.8% Rates from 72 U.S. hospitals in nine regions show variation by region 1 Rates are high and continue to rise 2 Demonstrates importance of using a treatment with broad ESBL coverage E. coli, Escherichia coli; ESBL, extended-spectrum β-lactamase; K. pneumoniae; KPC, Klebsiella pneumoniae carbapenemase; k. oxytoca, Klebsiella oxytoca; P. mirabilis, Proteus miribilis. WestSouth Central (16.2%) E. coli 13.2% K. pneumoniae 26.6% K. oxytoca 3.6% P. mirabilis 4.1% EastSouth Central (8.2%) E. coli 7.6% K. pneumoniae 9.8% K. oxytoca 12.9% P. mirabilis 3.4% Sources: 1. Castanheira et al. Antimicrob Agents Chemother 2014;58: ; 2. Infect Control Hosp Epidemiol Oct;38(10):
11 Days of Therapy CRE Cases A Carbapenem Sparing Drug is Needed Carbapenems are the empiric* drug of choice for ESBL coverage Leads to overuse of carbapenems and increased resistance 18,000,000 Carbapenem Use in U.S. & Europe1 Growth in Carbapenem-resistant Enterobacteriaceae in >3M Admissions in 192 U.S. Hospitals ,000, ,000,000 12,000, ,000, ,000, ,000,000 4,000,000 2,000, National Projection: 227,828 cases *Treatment without specific pathogen diagnosis Sources: 1. Decision Resources AMR Hospital Database; 2. Adapted from Schneider G. SHEA, Spring
12 XERAVA Market Opportunity
13 XERAVA Market Opportunity in the U.S. and EU5 Overall Market 25% High-risk Segment 20% Product Opportunity 40M Days of Therapy 10M Days of Therapy 2M Days of Therapy 88% is IV treatment Patients receiving broad spectrum antibiotics Patients receiving combination Gramnegative and Grampositive agents and anaerobic antibiotics Sources: and 2015 Decision Resources AMR Hospital Database; 2. Internal market research 13
14 XERAVA Focus in the U.S. and EU5 Product Opportunity 2 Million Patient Days of Therapy Second Line Empiric Therapy for Patients: Who have not improved on initial empiric therapy: Empiric Therapy for Patients: Tachypneic Tachycardic At risk of infection with resistant organisms, e.g.: Renally impaired Previous hospitalization Recent ICU stay Elderly LTC facility / SNF Previous C. diff infection 1.2M 400K 400K Hypotensive Febrile For Patients with Confirmed: ESBL AmpC MRSA VRE C. diff Sources: and 2015 Decision Resources AMR Hospital Database; 2. Internal market research 14
15 Comparison of Coverage Points of Differentiation CONTEPO TM ciai indication as monotherapy No need for dose adjusting in renally impaired patients Broad label allowing for empiric therapy Priced for empiric market MDR Enterobacteriaceae (ESBL-expressing) MDR Enterobacteriaceae (AmpC-expressing) MRSA and VRE Anaerobes (i.e. C. diff) Sources: Prescribing information for approved products. Public data presentations for investigational products. Active Intermediate activity or Breakpoint Dependent No 15
16 XERAVA Label: Clear Differentiation Provides Market Opportunities Efficacy Broad label not restricted to patients with limited or no alternative treatment options No need for combination therapy Convenience Twice daily 1mg/kg dosing with a 60 minute infusion No need for Therapeutic Drug Monitoring for any patient groups High clinical cure rates in patients with MDR pathogens, ESBLs, beta-lactamases and Acinetobacter No dose adjustment for patients with impaired renal function Safety Positive safety and tolerability profile No black box warning Ability to use in patients with penicillin and beta-lactam allergies No risk of Clostridium difficile Commercial Opportunity Large, growing patient population ESBL rates as high as 25% in some regions in the U.S. ciais are always polymicrobial and require combination therapy in 50% of patients Carbapenem and beta-lactam combination sparing 16
17 XERAVA Launch
18 XERAVA: Launched in the U.S. XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in patients 18 years of age and older FDA approved on August 27, 2018 EMA approved on September 20, 2018 Launched in the U.S. in mid-october 2018 Label supports broad use 18
19 Clear Strategy to Ensure XERAVA Commercial Success Susceptibility Testing Focused Launch Strategy Experienced Team Appropriate Patients Differentiated Compound Research Use Only testing material available months before launch (e-strips and discs) Multiple commercial testing options available at launch Hospital-only focused product Targeting top 60% of Gram-negative hospitals at launch Target additional 30% in 2019, leading to 90% of Gram-negative market Management team has >20 years in antibiotic space Sales team has >25 years in the antibiotic space, and has launched >20 hospital products Only company focused on ciai Label allows for empiric treatment Focused on two distinct patient segments: 1) risk of infection with resistant pathogen and 2) high-risk Broad clinical and in vitro coverage of the most prevalent key resistant pathogens No need for TDM No need to dose adjust in renally impaired patients No risk of C. diff 19
20 Breaking the Antibiotic Launch Trends 169 Accounts Ordered Antimicrobial Susceptibility tests (AST) For Research Use Only (RUO) 3 Commercially Available AST Eravacycline Mast Disk by Hardy Diagnostics Eravacycline MIC Strip by Liofilchem Sensititre Plate by Thermo Fisher 400 Formulary Reviews Planned or already approved by end of Q % acceptance rate Speaker Programs 55 Speakers trained and speaking All territories have pulled through programs 70% Accounts Reordering Source: TTPH data as of March 14,
21 Pipeline Programs
22 TP-271: Targeting Respiratory Infections Development program targets respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens Potent activity in vitro against Gram-negative and Gram-positive pathogens associated with respiratory tract infections NIAID funding supports development through phase 1 Qualified Infectious Disease Product and Fast Track designation by FDA for both IV and oral formulations Positive safety and pharmacokinetic data from IV single-ascending and multipleascending dose studies Oral multiple-ascending dose Phase 1 study complete 22
23 TP-6076: Targeting MDR Gram-Negative Infections Potent activity in vitro against multidrug-resistant Gram-negative pathogens, including Acinetobacter baumannii On CDC and WHO list of serious threats Associated with high morbidity and mortality Common infections associated with Acinetobacter spp. VABP/HABP, bloodstream, cuti, cabssti Positive safety and pharmacokinetic data in single- and multiple-ascending dose studies Phase 1 bronchopulmonary disposition study to begin in Q Selected to receive $4 million CARB-X funding to support development 23
24 TP-6076: Targeting MDR Gram-Negative Infections 55 Extremely Drug Resistant Acinetobacter baumannii 141 resistant Enterobacteriaceae spp. Antibiotic MIC 50/90 µg/ml Antibiotic MIC 50/90 µg/ml TP /0.063 Tigecycline 2/4 Minocycline 8/16 Tetracycline >32 Colistin 0.5/4 Meropenem >32 Gentamicin >32 TP /0.5 Tigecycline 0.5/2 Minocycline 8/>32 Tetracycline 16/>32 Colistin 0.25/>32 Meropenem 8/>32 Gentamicin 8/>32 *MIC 50/90 : Minimum Inhibitory Concentration: Lowest concentration of the antibiotic at which 50% and 90% of the isolates were inhibited 24
25 Leadership Team: Seasoned Expertise in Development and Commercialization of Anti-infectives Guy Macdonald President and Chief Executive Officer Larry Edwards Chief Operating Officer Larry Tsai, MD Chief Medical Officer Jacques Dumas, PhD Chief Scientific Officer Christopher Watt Senior Vice President, Finance Maria Stahl Senior Vice President, General Counsel 25
26
Combating Drug-Resistant Infections Globally. Company Presentation
Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationInfection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention
Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationKeeping Antibiotics Working: Nursing Leadership in Action
Keeping Antibiotics Working: Nursing Leadership in Action Pat McLaine, DrPH, MPH, RN Robyn Gilden, PhD, RN Department of Family and Community Health Maryland Nurses Association October 2016 US 2 million
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationAntimicrobial Stewardship. Where are we now and where do we need to go?
Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 @SPC2016Cork Antimicrobial Stewardship. Where are we now and where do we need to go? Frank O Riordan Antimicrobial pharmacist,
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationBreakthrough medicines targeting the growing global health threat of antibiotic resistance. Jefferies Healthcare Conference June 2017
Breakthrough medicines targeting the growing global health threat of antibiotic resistance Jefferies Healthcare Conference June 2017 June 2017 Our Mission To build an enduring biopharmaceutical company
More informationTestimony of the Natural Resources Defense Council on Senate Bill 785
Testimony of the Natural Resources Defense Council on Senate Bill 785 Senate Committee on Healthcare March 16, 2017 Position: Support with -1 amendments I thank you for the opportunity to address the senate
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationPreventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationEpidemiology and Economics of Antibiotic Resistance
Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationHuman health impacts of antibiotic use in animal agriculture
Human health impacts of antibiotic use in animal agriculture Beliefs, opinions, and evidence Peter Davies BVSc, PhD College of Veterinary Medicine, University of Minnesota, USA Terminology Antibiotic Compound
More informationGlobal Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016
Global Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016 Professor Visanu Thamlikitkul, MD Faculty of Medicine Siriraj Hospital, Mahidol University
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationThe threat of multidrug-resistant microorganisms and how to deal with it in Europe
The threat of multidrug-resistant microorganisms and how to deal with it in Europe Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial resistance and Healthcare-associated infections
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationHand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY
Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY MDROs and Hand Hygiene Guidelines HH Apr14 The Science of Hand Hygiene in Healthcare Settings
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationThe Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationPreserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationChallenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.
Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More information